Roland B. Walter - Concepedia

Author

Roland B. Walter

Also Known As

Boddu, Prajwal C, Dries Deeren, G Schoedon, R B Walter, R Walter, R. B. Walter, R. Walter, R.B. Walter, ROLAND WALTER, Rol B. Walter

695

Publications

19.3K

Citations

H-Index

180

Concepts

All Affiliations

Fred Hutch Cancer Center University of Washington The University of Texas MD Anderson Cancer Center University of Washington Medical Center Dana-Farber Cancer Institute

About

Roland B. Walter is an author at Fred Hutch Cancer Center specializing in medicine, hematology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	68	3.4K
2	Health Sciences	20	27	1.9K
3	Natural Sciences	3	3	52
4	Public Health	2	2	83
5	Arts	1	1	11

Roland B. Walter

187

Publications

12.9K

Citations

H-Index

Page 1

	Year	Citations
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study Andrew H. Wei, Stephen A. Strickland, Jing-Zhou Hou, Journal of Clinical Oncology	2019	680
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party Michael Heuser, Sylvie Freeman, Gert J. Ossenkoppele, Blood Mixed-phenotype Acute LeukemiaPathologyMeasurable Residual DiseaseMyeloid NeoplasiaHematological Malignancy	2021	666
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn L. Slovak, Blood	2013	621
Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Roland B. Walter, Ted Gooley, Brent L. Wood, Journal of Clinical Oncology	2011	394
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission? Daisuke Araki, Brent L. Wood, Megan Othus, Journal of Clinical Oncology	2015	385
SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey, Blood	2013	381
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission Roland B. Walter, Sarah Buckley, John M. Pagel, Blood	2013	350
Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment Roland B. Walter, Megan Othus, Gautam Borthakur, Journal of Clinical Oncology	2011	339
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Blood	2020	307
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia Margaret L. Green, Wendy M. Leisenring, Hu Xie, Blood	2013	304

Page 1